INNNEUROPHARM grants for 2 Polpharma projects
The Polpharmа Group has received co-funding for two projects as part of the INNONEUROPHARM sectoral programme supporting research projects in the pharmaceutical sector.
The following projects have received co-funding:
- Polpharma Biologics project: “Development of a universal model for preclinical pharmacokinetic testing of therapeutic monoclonal antibodies using the domestic pig animal model”.
The value of the grant is PLN 1,600,281.80
- Polfa SA Warsaw Pharmaceutical Works and Polpharma SA Pharmaceutical Works Consortium project: “Modern modified-release generic drug as alternative therapy for schizophrenia patients”.
The value of the grant is PLN 11,932,199.55.
Unlike the previous financial perspective the support for research projects is now focused on selected leading areas of science and economy which represent the development potential of Poland and its regions, or “smart specialisations”. Healthcare is one such specialisation, which includes pharmacy and biotechnology. The grants confirm the innovativeness of Polpharmа and prove that the direction of development chosen by the company is in line with the expectations of the modern Polish economy.
The INNNEUROPHARM programme was created upon the request of the Polish Union of Employers in Pharmaceutical Industry (PZPPF). It is one of the tools available for the support of research and development projects.
Other national initiatives supporting research projects include the Fast Track (Polish: “Szybka ścieżka”) programme in which Polpharma Biologics has received two grants for monoclonal antibody development projects.